Lyell Immunopharma Revenue vs. Price To Earning
| LYEL Stock | USD 0.95 0.03 3.26% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 130 K | Current Value 123.5 K | Quarterly Volatility 21.6 M |
For Lyell Immunopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lyell Immunopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lyell Immunopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lyell Immunopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lyell Immunopharma over time as well as its relative position and ranking within its peers.
Lyell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lyell Immunopharma Price To Earning vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lyell Immunopharma's current stock value. Our valuation model uses many indicators to compare Lyell Immunopharma value to that of its competitors to determine the firm's financial worth. Lyell Immunopharma is rated below average in revenue category among its peers. It is rated fourth overall in price to earning category among its peers . The ratio of Revenue to Price To Earning for Lyell Immunopharma is about 35,519 . At this time, Lyell Immunopharma's Total Revenue is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lyell Immunopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lyell Revenue vs. Competition
Lyell Immunopharma is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 98.31 Million. Lyell Immunopharma adds roughly 130,000 in revenue claiming only tiny portion of equities under Health Care industry.
Lyell Price To Earning vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Lyell Immunopharma |
| = | 130 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Lyell Immunopharma |
| = | 3.66 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Lyell Price To Earning Comparison
Lyell Immunopharma is currently under evaluation in price to earning category among its peers.
Lyell Immunopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lyell Immunopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lyell Immunopharma will eventually generate negative long term returns. The profitability progress is the general direction of Lyell Immunopharma's change in net profit over the period of time. It can combine multiple indicators of Lyell Immunopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -94 K | -98.7 K | |
| Net Interest Income | 23.5 M | 24.6 M | |
| Interest Income | 23.5 M | 24.6 M | |
| Operating Income | -247 M | -259.4 M | |
| Net Loss | -234.6 M | -246.4 M | |
| Income Before Tax | -234.6 M | -246.4 M | |
| Total Other Income Expense Net | 12.4 M | 13 M | |
| Net Loss | -164.8 M | -173 M | |
| Net Loss | -234.6 M | -246.4 M | |
| Income Tax Expense | -10.5 M | -11.1 M | |
| Non Operating Income Net Other | -32.9 M | -34.6 M | |
| Change To Netincome | 89.2 M | 75.4 M | |
| Net Loss | (0.93) | (0.98) | |
| Income Quality | 0.70 | 0.42 | |
| Net Income Per E B T | 0.03 | 0.03 |
Lyell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lyell Immunopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lyell Immunopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lyell Immunopharma's important profitability drivers and their relationship over time.
Use Lyell Immunopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lyell Immunopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lyell Immunopharma will appreciate offsetting losses from the drop in the long position's value.Lyell Immunopharma Pair Trading
Lyell Immunopharma Pair Trading Analysis
The ability to find closely correlated positions to Lyell Immunopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lyell Immunopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lyell Immunopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lyell Immunopharma to buy it.
The correlation of Lyell Immunopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lyell Immunopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lyell Immunopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lyell Immunopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lyell Immunopharma position
In addition to having Lyell Immunopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
To fully project Lyell Immunopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lyell Immunopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lyell Immunopharma's income statement, its balance sheet, and the statement of cash flows.